Human Apolipoprotein C-I from Human Plasma

<strong>Human Apolipoprotein C-I from Human Plasma</strong>_x000D_ <strong>Catalog number:</strong> B2016557_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 6.6 kDa_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> Apolipoprotein C-I, Apo-CI, ApoC-I, Apo-C1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Koska J, Furtado J, Hu Y, Sinari S, Budoff MJ, Billheimer D, Nedelkov D, McClelland RL, Reaven PD. Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis J Lipid Res. 2022 Sep;63(9):100263._x000D_ 2: Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity J Biol Chem. 2000 Dec 1;275(48):37504-9._x000D_ 3: Su M, Zhou Y, Wang D, Xu T, Chang W, Wang M, Yu X, Feng D, Han Z, Yan W. Expression and purification of recombinant human apolipoprotein C-I in Pichia pastoris Protein Expr Purif. 2011 Jul;78(1):22-6._x000D_ 4: Lahiry P, Cao H, Ban MR, Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Huff MW, Connelly PW, Hegele RA. APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians J Lipid Res. 2010 Apr;51(4):843-8._x000D_ 5: Liu M, Subbaiah PV. Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E Biochim Biophys Acta. 1993 Jun 12;1168(2):144-52._x000D_ 6: Rozek A, Sparrow JT, Weisgraber KH, Cushley RJ. Sequence-specific 1H NMR resonance assignments and secondary structure of human apolipoprotein C-I in the presence of sodium dodecyl sulfate Biochem Cell Biol. 1998;76(2-3):267-75._x000D_ 7: Sigler GF, Soutar AK, Smith LC, Gotto AM Jr, Sparrow JT. The solid phase synthesis of a protein activator for lecithin-cholesterol acyltransferase corresponding to human plasma apoC-I Proc Natl Acad Sci U S A. 1976 May;73(5):1422-6._x000D_ 8: Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN, Smith JD. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl J Clin Invest. 1996 Aug 1;98(3):846-55._x000D_ 9: Alaupovic P, Wang CS, McConathy WJ, Weiser D, Downs D. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product Arch Biochem Biophys. 1986 Jan;244(1):226-37._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/25682025">10: Asciutto G, Dias NV, Edsfeldt A, Alm R, Fredrikson GN, Gonçalves I, Nilsson J. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy Atherosclerosis. 2015 Apr;239(2):289-94. </a>_x000D_ _x000D_ <strong>Products Related to Human Apolipoprotein C-I from Human Plasma can be found at</strong> <a href="https://moleculardepot.com/product-category/Biofluids/"> Biofluids</a>